1036 ET - Merck's struggles with Gardasil aren't easing up. The drug maker disclosed 1Q sales of the treatment, which prevents cancers caused from the human papillomavirus, declined 41% to $1.33 billion, due primarily to lower demand in China. Gardasil's challenges were on display in the prior quarter when the company's guidance came up short of Wall Street's estimates and said it was pausing shipments to China of the treatment from February through at least the middle of the year. Gardasil is Merck's biggest-selling franchise behind blockbuster cancer therapy Keytruda, which saw sales increase 4% to $7.21 billion in the quarter. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
April 24, 2025 10:36 ET (14:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。